The Australian firm has taken aim at several firms in the research, molecular diagnostics, and agricultural genomics fields for allegedly infringing its patent covering methods of analyzing non-coding DNA sequences.
The Olympus Diagnostics business that Beckman Coulter acquired last summer provided a $120 million contribution for the fourth quarter. The firm beat analysts' consensus estimate, despite a drag from cash instrument sales during the quarter.
The automated benchtop system, called SPRIworks Fragment Library System I, is scheduled to be launched this quarter. It is capable of preparing up to 10 DNA libraries for the Illumina Genome Analyzer within five hours, according to Beckman.
A Beckman Coulter official provided an update on revenue guidance and the firm's pending molecular diagnostics system; while an Agilent executive discussed the company's pending Varian acquisition and new UHPLC system.
GE Healthcare charges in its complaint that kits and instruments sold by Beckman Coulter Genomics based on the Agencourt Solid Phase Reversible Immobilization, or SPRI, technology "contain instructions to use the products in a manner that infringes one or more claims of the '231 and/or '946 patents."